M
Michael Miller
Researcher at University of Maryland, Baltimore
Publications - 313
Citations - 25090
Michael Miller is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Medicine & Hypertriglyceridemia. The author has an hindex of 60, co-authored 286 publications receiving 21856 citations. Previous affiliations of Michael Miller include University of Rochester & University of Alabama at Birmingham.
Papers
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt,P. Gabriel Steg,Michael Miller,Eliot A. Brinton,Terry A. Jacobson,Steven B. Ketchum,Ralph T. Doyle,Rebecca A. Juliano,Lixia Jiao,Craig Granowitz,Jean-Claude Tardif,Christie M. Ballantyne,Reduce-It Investigators +12 more
TL;DR: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
Journal ArticleDOI
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller,Neil J. Stone,Christie M. Ballantyne,Vera Bittner,Michael H. Criqui,Henry N. Ginsberg,Anne C. Goldberg,William James Howard,Marc S. Jacobson,Penny M. Kris-Etherton,Terry A. Lennie,Moshe Levi,Theodore Mazzone,Subramanian Pennathur +13 more
TL;DR: The role of triglyceride-rich lipoproteins (TRLs) in the evaluation and management of CVD risk was discussed in this article, where the authors highlighted approaches aimed at minimizing the adverse public health-related consequences associated with hypertriglyceridemic states.
Journal ArticleDOI
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Allen J. Taylor,Todd C. Villines,Eric J. Stanek,Patrick Devine,Len Griffen,Michael Miller,Neil J. Weissman,Mark Turco +7 more
TL;DR: This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima-media thickness when combined with a statin and that niac in is superior to ezetimibe.
Journal ArticleDOI
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection
Toni I. Pollin,Coleen M. Damcott,Haiqing Shen,Sandra Ott,John Shelton,Richard B. Horenstein,Wendy S. Post,John C. McLenithan,John C. McLenithan,Lawrence F. Bielak,Patricia A. Peyser,Braxton D. Mitchell,Michael Miller,Jeffrey R. O'Connell,Alan R. Shuldiner,Alan R. Shuldiner +15 more
TL;DR: Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-ch cholesterol and lower levels of LDL-cholesterol, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.